Search Results - "D'ADAMO, David"

Appraising the Current Role of Chemotherapy for the Treatment of Sarcoma by D'Adamo, David R

“…Sarcomas are a heterogeneous group of relatively rare mesenchymal neoplasms. They can be grouped into two general categories: soft tissue sarcoma (STS) and…”
Get full text

Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor by Butrynski, James E, D'Adamo, David R, Hornick, Jason L, Dal Cin, Paola, Antonescu, Cristina R, Jhanwar, Suresh C, Ladanyi, Marc, Capelletti, Marzia, Rodig, Scott J, Ramaiya, Nikhil, Kwak, Eunice L, Clark, Jeffrey W, Wilner, Keith D, Christensen, James G, Jänne, Pasi A, Maki, Robert G, Demetri, George D, Shapiro, Geoffrey I

“…A subgroup of inflammatory myoblastic tumors (IMTs) have gene rearrangements that activate anaplastic lymphoma kinase (ALK). The authors report a case of IMT…”
Get full text

Is adjuvant chemotherapy useful for soft-tissue sarcomas? by D'adamo, David

Get full text

Sarcoma by Skubitz, Keith M., MD, D'Adamo, David R., MD, PhD

“…Sarcomas comprise a heterogeneous group of mesenchymal neoplasms. They can be grouped into 2 general categories, soft tissue sarcoma and primary bone sarcoma,…”
Get full text

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial by Schöffski, Patrick, Prof, Chawla, Sant, MD, Maki, Robert G, Prof, Italiano, Antoine, MD, Gelderblom, Hans, Prof, Choy, Edwin, MD, Grignani, Giovanni, MD, Camargo, Veridiana, MD, Bauer, Sebastian, MD, Rha, Sun Young, MD, Blay, Jean-Yves, Prof, Hohenberger, Peter, MD, D'Adamo, David, MD, Guo, Matthew, PhD, Chmielowski, Bartosz, MD, Le Cesne, Axel, MD, Demetri, George D, Prof, Patel, Shreyaskumar R, Prof

“…Summary Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. In this phase 3…”
Get full text

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study by Tolaney, Sara M, Kalinsky, Kevin, Kaklamani, Virginia G, D'Adamo, David R, Aktan, Gursel, Tsai, Michaela L, O'Regan, Ruth M, Kaufman, Peter A, Wilks, Sharon T, Andreopoulou, Eleni, Patt, Debra A, Yuan, Yuan, Wang, Grace, Savulsky, Claudio, Xing, Dongyuan, Kleynerman, Ella, Karantza, Vassiliki, Diab, Sami

“…As monotherapies, eribulin (chemotherapy) and pembrolizumab (immunotherapy) have shown promise for patients with metastatic triple-negative breast cancer…”
Get full text

Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas by Italiano, Antoine, Cioffi, Angela, Penel, Nicolas, Levra, Matteo Giaj, Delcambre, Corinne, Kalbacher, Elsa, Chevreau, Christine, Bertucci, François, Isambert, Nicolas, Blay, Jean‐Yves, Bui, Binh, Antonescu, Cristina, D'Adamo, David R., Maki, Robert G., Keohan, Mary Louise

“…BACKGROUND: Data regarding the role of anthracyclines and taxanes as first‐line treatments of metastatic angiosarcoma are limited. METHODS: Records of 117…”
Get full text

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial by LUKE, Jason J, D'ADAMO, David R, DICKSON, Mark A, KEOHAN, Mary Louise, CARVAJAL, Richard D, MAKI, Robert G, DE STANCHINA, Elisa, MUSI, Elgilda, SINGER, Samuel, SCHWARTZ, Gary K

“…Dysregulated cyclin-dependent kinases are important to the growth of some sarcomas. Flavopiridol is a pan-CDK inhibitor that has been shown to potentiate…”
Get full text

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas by MAKI, Robert G, D'ADAMO, David R, TAKIMOTO, Chris H, KRAFT, Andrew S, ELIAS, Anthony D, BROCKSTEIN, Bruce, BLACHERE, Nathalie E, EDGAR, Mark A, SCHWARTZ, Lawrence H, QIN, Li-Xuan, ANTONESCU, Cristina R, SCHWARTZ, Gary K, KEOHAN, Mary L, SAULLE, Michael, SCHUETZE, Scott M, UNDEVIA, Samir D, LIVINGSTON, Michael B, COONEY, Matthew M, HENSLEY, Martee L, MITA, Monica M

“…PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in…”
Get full text

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy by Choy, Edwin, Butrynski, James E, Harmon, David C, Morgan, Jeffrey A, George, Suzanne, Wagner, Andrew J, D'Adamo, David, Cote, Gregory M, Flamand, Yael, Benes, Cyril H, Haber, Daniel A, Baselga, Jose M, Demetri, George D

“…Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate…”
Get full text

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas by GEORGE, Suzanne, MERRIAM, Priscilla, MORGAN, Jeffrey, SCHWARTZ, Gary K, WAGNER, Andrew J, BUTRYNSKI, James E, DEMETRI, George D, KEOHAN, Mary L, MAKI, Robert G, VAN DEN ABBEELE, Annick D, YAP, Jeffrey T, AKHURST, Timothy, HARMON, David C, BHUCHAR, Gauri, O'MARA, Margaret M, D'ADAMO, David R

“…PURPOSE To evaluate the potential benefit of continuous daily dosing sunitinib in patients with advanced nongastrointestinal stromal tumor (GIST) sarcomas…”
Get full text

An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions by Lowery, Maeve A., Kelsen, David P., Stadler, Zsofia K., Yu, Kenneth H., Janjigian, Yelena Y., Ludwig, Emmy, D'Adamo, David R., Salo‐Mullen, Erin, Robson, Mark E., Allen, Peter J., Kurtz, Robert C., O'Reilly, Eileen M.

“…Learning Objectives After completing this course, the reader will be able to: Describe the genetic syndromes associated with pancreas adenocarcinoma. Explain…”
Get full text

Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) by de Camargo, Veridiana Pires, Keohan, Mary L., D'Adamo, David R., Antonescu, Cristina R., Brennan, Murray F., Singer, Samuel, Ahn, Linda S., Maki, Robert G.

“…BACKGROUND: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to…”
Get full text

Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma by SHAH, Manish A, RAMANATHAN, Ramesh K, SCHWARTZ, Gary K, KELSEN, David P, ILSON, David H, LEVNOR, Alissa, D'ADAMO, David, O'REILLY, Eileen, TSE, Archie, TROCOLA, Robin, SCHWARTZ, Lawrence, CAPANU, Marinela

“…Bevacizumab improves survival in several solid tumor malignancies when combined with chemotherapy. We evaluated the efficacy and safety of the addition of…”
Get full text

Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas by D'ADAMO, David R, ANDERSON, Sibyl E, ALBRITTON, Karen, YAMADA, Jennifer, RIEDEL, Elyn, SCHEU, Kelly, SCHWARTZ, Gary K, CHEN, Helen, MAKI, Robert G

“…To evaluate the antitumor activity and tolerability of bevacizumab and doxorubicin in patients with metastatic soft-tissue sarcoma (STS). Patients may have had…”
Get full text

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours by Jones, Robin L., Ratain, Mark J., O'Dwyer, Peter J., Siu, Lillian L., Jassem, Jacek, Medioni, Jacques, DeJonge, Maja, Rudin, Charles, Sawyer, Michael, Khayat, David, Awada, Ahmad, de Vos-Geelen, Judith M.P.G.M., Evans, T.R. Jeffry, Obel, Jennifer, Brockstein, Bruce, DeGreve, Jacques, Baurain, Jean-Francois, Maki, Robert, D'Adamo, David, Dickson, Mark, Undevia, Samir, Geary, David, Janisch, Linda, Bedard, Philippe L., Abdul Razak, Albiruni R., Kristeleit, Rebecca, Vitfell-Rasmussen, Joanna, Walters, Ian, Kaye, Stan B., Schwartz, Gary

“…Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised…”
Get full text

A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors by D'Adamo, David R., Dickson, Mark A., Keohan, Mary L., Carvajal, Richard D., Hensley, Martee L., Hirst, Catherine M., Ezeoke, Marietta O., Ahn, Linda, Qin, Li‐Xuan, Antonescu, Cristina R., Lefkowitz, Robert A., Maki, Robert G., Schwartz, Gary K., Tap, William D.

“…Background Sorafenib and dacarbazine have low single‐agent response rates in metastatic sarcomas. As angiogenesis inhibitors can enhance the efficacy of…”
Get full text

Advances in the treatment of gastrointestinal stromal tumor by D’Adamo, David

“…GIST (gastrointestinal stromal tumor) is a rare soft tissue malignancy arising in the gut. It has become well known recently because of the effectiveness of…”
Get full text

A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) by Schafer, Eric S., Rau, Rachel E., Berg, Stacey, Liu, Xiaowei, Minard, Charles G., D'Adamo, David, Scott, Rachael, Reyderman, Larisa, Martinez, Gresel, Devarajan, Sandhya, Reid, Joel M., Fox, Elizabeth, Weigel, Brenda J., Blaney, Susan M.

“…Background Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin…”
Get full text

Integrating Novel Therapies Into the Treatment of Sarcoma: A Multidisciplinary Approach—Introduction by D'Adamo, David R., MD, PhD

Get full text